Bristol Myers (BMY) Stock: Here’s What You Need To Know

Bristol Myers (NYSE:BMY) On August 5, 2016 Bristol Myers had a very rough day with respect to one of its targets in the pipeline.  The company’s PD-1 immune checkpoint inhibitor, known as Opdivo, failed to meet the primary endpoint of a phase 3 clinical trial. Bristol Myer’s stock did not have a good day after … Read more

Relypsa Stock (RLYP): Here’s What You Need To Know

Relypsa Inc. (NASDAQ: RLYP) On July 21, 2016 shares of Relypsa soared higher by 58% after it was announced that Swedish drug maker Galencia purchased the company. Galencia had bought Relypsa in an all cash deal for $32 per share or $1.53 billion. There are two reasons why Galencia had paid so much to acquire … Read more

Juno Therapeutics (JUNO) Stock: Here’s What You Need To Know

Juno Therapeutics (NASDAQ: JUNO) On July 12, 2016 it was announced that the FDA had released the clinical hold for the company’s lead drug candidate  JCAR015. A few weeks prior the FDA had put Juno’s trial, known as ROCKET, on a clinical hold because there were two patient deaths in the trial. The company proclaimed … Read more

Regulus Therapeutics (RGLS) Stock | Here’s What You Need To Know

Regulus Therapeutics (NASDAQ:RGLS) In after-hours trade on Monday June 27, 2016 shares of Regulus Therapeutics tanked as much as 60% after the company announced that the FDA had placed their Hepatitis C drug on a clinical hold. It is not a good thing that the company’s drug, RG-101 has been placed on a clinical hold. … Read more

Biotech Stock News (INO) (NYMX)

Inovio Pharmaceuticals (NASDAQ:INO) On Monday June 20, 2016 Inovio Pharmaceuticals along with one of its subsidiaries Gene One Life Sciences have received authorization from the FDA to begin a first ever trial in humans targeting the Zika Virus. This is a monumental event, because it will the first trial ever to begin treating humans with … Read more

Biotech Stock News (SRPT)(SPHS)

Sarepta Therapeutics (NASDAQ:SRPT) On Monday June 6, 2016 shares of Sarepta Therapeutics were up more than 31% in after-hours trade after the company announced that the FDA had requested for additional data for the Eteplirsen decision. The market clearly viewed the fact that the FDA needed more data as a positive. Which is why shares … Read more

Biotech Stock News (STEM) (SRPT)

StemCells Inc. (NASDAQ:STEM) On Tuesday May 31, 2016 shares of Stemcells fell by more than 83% after the company announced that it would completely stop its phase 2 Pathway study. The phase 2 study used Stem’s HuCNS-SC human neural stem cells to treat spinal cord injury. This was a huge shock for investors, because the … Read more

Biotech Stock News (RXII) (CLVS) (AZN)

Rxi Pharmaceuticals (NASDAQ:RXII) On May 3, 2016 Rxi Pharmaceuticals announced that it had entered into a license agreement with Thera NeuroPharma for the treatment of ALS or Lou Gherig’s Disease. ALS stands for amyotrophic lateral sclerosis, and is a debilitating disease where nerves in the muscles breakdown reducing/eliminating movement. Rxi entered the agreement with this … Read more

Biotech Stock News (SRPT) (BMRN) (ACAD)

Sarepta Therapeutics (NASDAQ:SRPT) On Monday April 25, 2016 Sarepta Therapeutics had an FDA advisory panel shoot down its drug Eteplirsen, used to treat patients with Duchenne Muscular Dystrophy — DMD. The panel voted against Eteplirsen on all questions. Even the last question which asked if Eteplirsen should be approved for DMD patients was also voted … Read more

Biotech Stock News (RXII) (SRPT)

Rxi Pharmaceuticals (NASDAQ:RXII) On Tuesday April 19, 2016 Rxi Pharmaceuticals announced that it would present pre-clinical data at a medical conference, known as 2016 ARVO Conference. ARVO stands for Association for Research in Vision and Ophthalmology. The pre-clinical data to be presented will be the company’s drug in corneal scarring. In order to prevent injury … Read more